Enteral Route Nanomedicine for Cancer Therapy
Lin-Zhu Zhang,Rui-Jie Du,Duo Wang,Juan Qin,Chao Yu,Lei Zhang,Hai-Dong Zhu
DOI: https://doi.org/10.2147/ijn.s482329
IF: 7.033
2024-09-26
International Journal of Nanomedicine
Abstract:Lin-Zhu Zhang, &ast Rui-Jie Du, &ast Duo Wang, &ast Juan Qin, Chao Yu, Lei Zhang, Hai-Dong Zhu Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lei Zhang; Hai-Dong Zhu, Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, People's Republic of China, Email ; With the in-depth knowledge of the pathological and physiological characteristics of the intestinal barrier–portal vein/intestinal lymphatic vessels–systemic circulation axis, oral targeted drug delivery is frequently being renewed. With many advantages, such as high safety, convenient administration, and good patient compliance, many researchers have begun to explore targeted drug delivery from intravenous injections to oral administration. Over the past few decades, the fields of materials science and nanomedicine have produced various drug delivery platforms that hold great potential in overcoming the multiple barriers associated with oral drug delivery. However, the oral transport of particles into the systemic circulation is extremely difficult due to immune rejection and biochemical invasion in the intestine, which limits absorption and entry into the bloodstream. The feasibility of the oral delivery of targeted drugs to sites outside the gastrointestinal tract (GIT) is unknown. This article reviews the biological barriers to drug absorption, the in vivo fate and transport mechanisms of drug carriers, the theoretical basis for oral administration, and the impact of carrier structural evolution on oral administration to achieve this goal. Finally, this article reviews the characteristics of different nano-delivery systems that can enhance the bioavailability of oral therapeutics and highlights their applications in the efficient creation of oral anticancer nanomedicines. Keywords: oral nanomedicine, oral targeted drug delivery, nanoparticles, cancer treatment, biological barriers Graphical The route of drug administration is the most important factor in determining drug concentration and residence time at the target site. 1,2 Despite well-known drawbacks such as poor drug bioavailability and rapid degradation rates and metabolism in the intestine and liver, oral therapy is considered the most ideal and convenient route of drug delivery for both systemic and local administration drug delivery. 3 It is essential for patients to perceive oral drug delivery positively, particularly when compared to infusions or other parenteral methods, which are common in cancer treatments. Additionally, the economic benefits of reducing hospital stays for patients should also be considered. 4 The gastrointestinal tract (GIT) encompasses a surface area of approximately 300 square meters and is enveloped with a sticky mucosal layer that aids in the adhesion and absorption of drugs. 5 Notwithstanding, oral drug delivery poses a daunting task owing to the intricate nature of the GIT and the impediments to drug delivery, such as substandard solubility, stability, and permeability. In addition, an unpleasant taste, gastric irritation, and susceptibility to intestinal and liver barrier metabolism are common drawbacks of oral medications. 6,7 However, targeted delivery to specific locations in the GIT can be achieved through appropriate drug design or delivery vehicles. 8 The residence time of digested food in the duodenum is relatively brief, and the pH is lower than that of the remainder of the small intestine. This indicates that the retention of drugs in the duodenum can be successfully avoided by increasing the pKa value of the delivery vehicle. For instance, Lozoya-Agullo et al employed poly(lactic-co-glycolic) acid (PLGA) nanoparticles for colonic delivery, demonstrating that drug release in the duodenum could be significantly avoided due to insufficient ambient pH. 9 Drug delivery systems (DDSs) are frequently utilized to improve the stability of drugs, regulate drug release, and accumulate drugs at the lesion site, thus improving drug effectiveness. 10–13 In 1906, Ehrlich first proposed the "magic bullet" hypothesis, which i -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology